U.S. FDA approves first mRNA flu shot from Moderna

Moderna’s FDA approval for mFlusiva—the first mRNA seasonal flu vaccine—covers adults 50–64 (traditional) and 65+ (accelerated). In a late-stage trial of 40,000+ adults 50+, the shot was 26.6% more effective than a licensed standard-dose flu vaccine, and it showed stronger antibody responses than Sanofi’s high-dose vaccine in those 65+. Analysts expect limited revenue impact until H2 2027 (after missing the 2026 contracting cycle), but Jefferies previously modeled $750M in U.S. sales by 2030; the approval also follows heightened FDA vaccine scrutiny and leadership turnover.

Analysis

This is mostly a credibility milestone for MRNA, not an earnings event. The market will want to extrapolate approval into near-term flu revenue, but the economics are pushed out and the real value is whether this converts mRNA from a COVID-only story into a durable seasonal platform with pricing power in the senior segment.

The competitive read-through is more nuanced than a simple share-grab narrative. SNY and GSK have the most to lose over time because the highest-margin flu pool sits in older adults, where switching is driven less by headline efficacy and more by formulary placement, pharmacy execution, and recommendation status. That means any displacement is likely to be slow and lumpy; the first derivative impact is on valuation multiples for vaccine incumbents, not 2026 sales.

The main risk is that the confirmatory path for the older cohort becomes the bottleneck and the combo vaccine story stays out of reach. If contracting slips again or the next efficacy package is merely non-inferior rather than clearly superior, the stock can give back the approval pop quickly. The contrarian view is that the Street may be underestimating how sticky the senior flu market is, which argues against a large short in SNY/GSK today, but also means MRNA needs multiple clean execution points over 12-18 months before this becomes a real franchise change.

Key Decisions for Investors

• MRNA: do not chase the first-day move; wait for a 10-15% pullback to initiate a small tactical long with a 12-18 month horizon. Risk/reward is tied to the next contracting cycle and confirmatory data, not 2026 revenue.
• MRNA: for those wanting upside exposure without balance-sheet risk, use 2027/2028 call spreads instead of common stock. This captures platform-validation optionality while limiting downside if flu monetization remains delayed.
• Pair trade for a 2026-27 view only: long MRNA / short SNY or GSK on evidence of payer and pharmacy-channel acceptance. Abort if senior share does not start to move by the 2027 contracting season or if incumbent flu franchise guidance proves stable.
• Set a watch item on ACIP/CDC language and Moderna's 65+ confirmatory package; if those slip, fade any strength in MRNA and avoid shorting the incumbents aggressively until adoption data is visible.